RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignancies

References

• Pagano L, Salmanton-García J, Marchesi F, Busca A, Corradini P, Hoenigl M, Klimko N, Koehler P, Pagliuca A, Passamonti F, et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol. 2021;14(1):168. doi:10.1186/s13045-021-01177-0.
   PubMed Web of Science ®Google Scholar
• Bange EM, Han NA, Wileyto P, Wileyto P, Kim JY, Gouma S, Robinson J, Greenplate AR, Hwee MA, Porterfield F, Owoyemi O, Naik K. CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med. 2021 Jul;27(7):1280–9.
   PubMed Web of Science ®Google Scholar
• Goubet A-G, Dubuisson A, Geraud A, Danlos F-X, Terrisse S, Silva CAC, Drubay D, Touri L, Picard M, Mazzenga M, et al. Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis. Cell Death Differ. 2021;28(12):3297–3315. doi:10.1038/s41418-021-00817-9.
   PubMed Web of Science ®Google Scholar
• Fahrner J-E, Lahmar I, Goubet A-G, Haddad Y, Carrier A, Mazzenga M, Drubay D, Alves Costa Silva C, de Sousa E, Thelemaque C, et al. The polarity and specificity of antiviral t lymphocyte responses determine susceptibility to SARS-CoV-2 infection in patients with cancer and healthy individuals. Cancer Discov. 2022;12(4):958–983. doi:10.1158/2159-8290.CD-21-1441.
   PubMed Web of Science ®Google Scholar
• Teh JSK, Coussement J, Neoh ZCF, Spelman T, Lazarakis S, Slavin MA, Teh BW. Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis. Blood Adv. 2022;6(7):2014–2034. doi:10.1182/bloodadvances.2021006333.
   PubMed Web of Science ®Google Scholar
• Agha ME, Blake M, Chilleo C, Wells A, Haidar G. Suboptimal response to coronavirus disease 2019 messenger RNA vaccines in patients with hematologic malignancies: a need for vigilance in the postmasking era. Open Forum Infect Dis. 2021;8(7):ofab353. doi:10.1093/ofid/ofab353.
   PubMed Web of Science ®Google Scholar
• Chung DJ, Shah GL, Devlin SM, Ramanathan LV, Doddi S, Pessin MS, Hoover E, Marcello LT, Young JC, Boutemine SR, et al. Disease- and therapy-specific impact on humoral immune responses to COVID-19 vaccination in hematologic malignancies. Blood Cancer Discov. 2021;2(6):568–576. doi:10.1158/2643-3230.BCD-21-0139.
   PubMedGoogle Scholar
• Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. Cancer Cell. 2021;39(8):1031–1033. doi:10.1016/j.ccell.2021.07.012.
   PubMed Web of Science ®Google Scholar
• Mouton W, Compagnon C, Saker K, Daniel S, Lacoux X, Pozzetto B, Oriol G, Djebali S, Berthier F, Marvel J, Walzer T. A novel whole-blood stimulation assay to detect and quantify memory T-cells in COVID-19 patients. medRxiv. 2021;21253202.
   Google Scholar
• Chari A, Samur MK, Martinez-Lopez J, Cook G, Biran N, Yong K, Hungria V, Engelhardt M, Gay F, García Feria A, et al. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the international myeloma society data set. Blood. 2020;136(26):3033–3040. doi:10.1182/blood.2020008150.
   PubMed Web of Science ®Google Scholar
• Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, Chen P, Söderdahl G, Österborg A, Smith CIE, Wullimann D, et al. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. EBioMedicine. 2021;74:103705. doi:10.1016/j.ebiom.2021.103705.
   PubMed Web of Science ®Google Scholar
• Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, Rahman S, Kim SY, Ko B, Sica RA, et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell. 2021;39(8):1081–1090.e2. doi:10.1016/j.ccell.2021.06.002.
   PubMed Web of Science ®Google Scholar
• Maneikis K, Šablauskas K, Ringelevičiūtė U, Vaitekėnaitė V, Čekauskienė R, Kryžauskaitė L, Naumovas D, Banys V, Pečeliūnas V, Beinortas T, et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematol. 2021;8(8):e583–e592. doi:10.1016/S2352-3026(21)00169-1.
   PubMed Web of Science ®Google Scholar
• Benda M, Mutschlechner B, Ulmer H, Grabher C, Severgnini L, Volgger A, Reimann P, Lang T, Atzl M, Huynh M, et al. Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients. Br J Haematol. 2021;195(4):523–531. doi:10.1111/bjh.17743.
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, Morales M, Ziv T, Shorer Arbel Y, Scarfò L, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137(23):3165–3173. doi:10.1182/blood.2021011568.
   PubMed Web of Science ®Google Scholar
• Apostolidis SA, Kakara M, Painter MM, Goel RR, Mathew D, Lenzi K, Rezk A, Patterson KR, Espinoza DA, Kadri JC, Markowitz DM. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med. 2021;27(11):1990–2001. doi:10.1038/s41591-021-01507-2.
   PubMed Web of Science ®Google Scholar
• Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145–173. doi:10.1146/annurev.iy.07.040189.001045.
   PubMed Web of Science ®Google Scholar
• Jaganathan S, Stieber F, Rao SN, Nikolayevskyy V, Manissero D, Allen N, Boyle J, Howard J. Preliminary evaluation of QuantiFERON SARS-CoV-2 and QIAreach Anti-SARS-CoV-2 total test in recently vaccinated individuals. Infect Dis Ther. 2021;10(4):2765–2776. doi:10.1007/s40121-021-00521-8.
   PubMed Web of Science ®Google Scholar
• Lee A, Wimmers F, Pulendran B. Epigenetic adjuvants: durable reprogramming of the innate immune system with adjuvants. Curr Opin Immunol. 2022;77:102189. doi:10.1016/j.coi.2022.102189.
   PubMed Web of Science ®Google Scholar
• Li C, Lee A, Grigoryan L, Arunachalam PS, Scott MKD, Trisal M, Wimmers F, Sanyal M, Weidenbacher PA, Feng Y, et al. Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. Nat Immunol. 2022;23(4):543–555. doi:10.1038/s41590-022-01163-9.
   PubMed Web of Science ®Google Scholar
• Heitmann JS, Bilich T, Tandler C, Nelde A, Maringer Y, Marconato M, Reusch J, Jäger S, Denk M, Richter M, et al. A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. Nature. 2022;601(7894):617–622. doi:10.1038/s41586-021-04232-5.
   PubMed Web of Science ®Google Scholar
• Pardieck IN, van der Sluis TC, van der Gracht ETI, Veerkamp DMB, Behr FM, van Duikeren S, Beyrend G, Rip J, Nadafi R, Beyranvand Nejad E, et al. A third vaccination with a single T cell epitope confers protection in a murine model of SARS-CoV-2 infection. Nat Commun. 2022;13(1):3966. doi:10.1038/s41467-022-31721-6.
   PubMed Web of Science ®Google Scholar
• Kumar A, Blum J, Thanh Le T, Havelange N, Magini D, Yoon IK. The mRNA vaccine development landscape for infectious diseases. Nat Rev Drug Discov. 2022;21(5):333–334. doi:10.1038/d41573-022-00035-z.
   PubMed Web of Science ®Google Scholar